Regulation & Compliance

EPAM and Google Cloud are moving beyond general AI, launching seven production-ready agents designed to solve specific, complex industry problems.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

A key consumer protection rule for airline delays has been reversed. Explore how this policy shift creates new risks for travelers and opportunities for insurers.

A new report on AI in the energy sector reveals a critical truth for medicine: general-purpose AI is not ready for high-stakes decisions without human experts.

Accenture is training 30,000 pros on Anthropic's Claude AI, tackling the biggest barrier to enterprise AI: moving from costly experiments to real value.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

Veritone is letting police control their own AI, offering a new model for data security that could transform law enforcement and rebuild public trust.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

New AI tech lets car dealers profile you on arrival. It promises efficiency, but at what cost to your privacy and power in the negotiation?

BingX aims to democratize crypto trading with a new partner, but our investigation reveals Trade4Me is unregulated and flagged for potential fraud.

CityHealth's 2025 report shows local policy is potent medicine. Discover how cities like Chicago are using data to tackle health, from housing to greenspace.

Amid rapid expansion and heightened regulatory scrutiny, PACS Group hires new compliance and HR chiefs to fortify its operational foundation for the future.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

With its finances in distress, Netcapital bets its future on blockchain and a new CEO. Can a turnaround specialist navigate the crypto frontier?

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

Lifestyle experts are shaping your holiday shopping. We dissect the strategy behind curated gift guides, influencer endorsements, and the media firms driving them.

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

A new Canada-Germany digital alliance promises AI and quantum breakthroughs. But can this pact move from policy to patients and transform Canadian health?